Results 41 to 50 of about 8,768 (188)
Review of bosentan in the management of pulmonary arterial hypertension [PDF]
, 2007 The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which is effective in the treatment of pulmonary arterial hypertension (PAH).
John Fraser +5 more
core
A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside
Interdisciplinary Medicine, EarlyView.This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione +2 more
wiley +1 more source
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. [PDF]
PLoS ONE, 2012 Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and ...
John Gatfield +4 more
doaj +1 more source
, 2006 Bosentan has lately been described as a successful therapeutic agent for portopulmonary hypertension consecutive to child A cirrhosis. This is the first report of the effect of this substance with advanced liver cirrhosis (child C) and renal ...
Nicod, Laurent P +4 more
core +1 more source
Succinct Synthesis of Bosentan Utilizing Glycol Mono-THP Ether
, 2014 A concise synthetic method for bosentan, a nonpeptide orally active dual endothelin (ET-1A/B) receptor antagonist used for the treatment of pulmonary artery hypertension (PAH), was developed.
Sang Yeul Lee (200286) +2 more
core +2 more sources
Molecular Cancer, 2010 Background The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma
Ballmer Andrea +5 more
doaj +1 more source
Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension [PDF]
Journal of Cardiovascular and Thoracic Research, 2019 Introduction: Pulmonary arterial hypertension (PAH) specific drug therapy using bosentan has significantly improved quality of life and survival, although PAH is still an incurable disease.
Shutan Liao +4 more
doaj +1 more source
Drug Delivery, 2017 Bosentan is an endothelin receptor antagonist (ERA) prescribed for patients with pulmonary arterial hypertension (PAH). The oral delivery of bosentan possesses several drawbacks such as low bioavailability (about 50%), short duration of action, frequent ...
Lydia A. Hanna +2 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundEvidence of the clinical safety of endothelin receptor antagonists (ERAs) is limited and derived mainly from individual trials; therefore, we conducted a meta‐analysis.
Anhua Wei +6 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen +3 more
wiley +1 more source